Global Classical Swine Fever Vaccines Market Size, Share, and COVID-19 Impact Analysis, By Source (Tissue Culture Origin and Cell Line Origin), By Application (Government Tender and Market Sales), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035.

Global Classical Swine Fever Vaccines Market Insights Forecasts to 2035

• The Global Classical Swine Fever Vaccines Market Size Was Estimated at USD 168.5 Million in 2025
• The Market Size is Expected to Grow at a CAGR of around 5.27% from 2026 to 2035
• The Worldwide Classical Swine Fever Vaccines Market Size is Expected to Reach USD 281.5 Million by 2035

Key Takeaways -

• Asia Pacific dominated the market with the largest share in 2025.
• Europe is expected to grow the fastest during the forecast period.
• By source, the tissue culture origin segment dominates the market with the largest share of about 66.0%, while the cell line origin segment is the emerging segment in the market.
• By application, the market sales segment is anticipated to hold the dominant share of around 95.0%; on the other hand, the government tender segment is emerging in the classical swine fever vaccines market.

According to a research report published by Spherical Insights and Consulting, the Global Classical Swine Fever Vaccines Market size was worth around USD 168.5 Million in 2025 and is predicted to grow to around USD 281.5 Million by 2035 with a compound annual growth rate (CAGR) of 5.27% from 2026 and 2035. The market for classical swine fever vaccines has a number of opportunities to grow due to the growing animal disease awareness, government investment in immunization, and increased fatality of CSF requiring robust preventative measures.

Key Trends in Classical Swine Fever Vaccines Market –

• Growing demand for marker vaccines (DIVA strategy) for differentiating infected from vaccinated animals
• International trade and investment in biotechnology for safer, more effective modified live vaccines

Market Overview

The global classical swine fever vaccines industry is a market emphasizing on producing attenuated live vaccines, like those derived from the Lapinized virus or tissue culture, to prevent high mortality rates, especially in major pork-producing regions. It is an important sector of the broader porcine biologics industry, driven by the need to control highly contagious viral diseases in swine populations. Classical swine fever vaccines are highly effective biological products designed to prevent and control hog cholera, a contagious viral disease in pigs. Classical swine fever (CSF) vaccination is the primary control method for this contagious, often fatal viral disease. An increasing pork consumption and strict government-led vaccination programs for food security are the primary driving factors in the classical swine fever vaccines market.

Innovation and market expansion are anticipated as a result of major players' growing R&D expenditures and the expanding partnerships. For instance, in February 2025, India administered 107.34 Crore FMD vaccine doses, strengthening livestock health initiatives.     

Report Coverage

This research report categorizes the classical swine fever vaccines market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the classical swine fever vaccines market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the classical swine fever vaccines market. 

Driving Factors

Growing prevalence of classical swine fever

In the global swine industry, classical swine fever (CSF), an extremely contagious viral disease, affects domestic pigs as well as wild boars. Despite the implementation of immunization and control efforts, a comprehensive meta-analysis of the incidence of CSF worldwide revealing significant geographical variation, with pooled prevalence estimates that are particularly high in Asian countries like China and Vietnam. While in India, the pooled estimate of prevalence of CSF under the random effective model revealed 45% (95% confidence interval: 35, 55%) in India.

Increasing pork consumption

Pork constitutes a significant portion (34%) of global meat intake, underscoring its importance in diets globally. This high percentage indicates pork’s popularity, driven by its flavor, versatility in cooking, and cultural significance in many regions. Current pork consumption stands at about 131,040 kilotons, with an expected rise to about 131,500 kilotons by 2031, a very modest increase, suggesting stability in pork demand. Increased pork consumption is driving market growth, with a strong emphasis on controlling classical swine fever to protect supply.

Government support and technological advancement

Government-led vaccination programs for disease control are promoting the classical swine fever vaccines market. For instance, the classical swine fever (CSF) control programme (CSF-CP) aims to control classical swine fever (CSF) through a mass vaccination campaign, focusing on vaccinating all healthy, non-pregnant pigs over three months of age with the CSF vaccine.  

Furthermore, technological advancements in classical swine fever vaccine production for more safer and precision is driving the market growth. Key innovation include recombinant subunit vaccines using E2 glycoproteins, mRNA technology, and DIVA (Differentiating Infected from Vaccinated Animals) strategies. 

Restraining Factors

High cost and stringent import bans

Stringent international trade policies, increased costs of modern subunit vaccines, and competition from rigorous biosecurity measures are restraining the classical swine fever vaccines market.

Market Segmentation

The Classical Swine Fever Vaccines Market share is classified into source and application.   

• The tissue culture origin segment dominated the market with the largest share of about 66.0% in 2025 and is projected to grow at a substantial CAGR during the forecast period.

Based on the source, the classical swine fever vaccines market is divided into tissue culture origin and cell line origin. Among these, the tissue culture origin segment dominated the market with the largest share of about 66.0% in 2025 and is projected to grow at a substantial CAGR during the forecast period. This is due to its increased production yields, improved standardization, and higher safety. While the cell line origin segment is the emerging segment in the classical swine fever vaccines market, driven by the advancement in cell-adapted vaccines to improve safety, the virulence of African Swine Fever (ASF), and the need to control endemic CSF.    

• The market sales segment accounted for the dominant market share of about 95.0% in 2025 and is projected to grow at a substantial CAGR during the forecast period.

Based on the application, the classical swine fever vaccines market is divided into government tender and market sales. Among these, the market sales segment accounted for the dominant market share of about 95.0% in 2025 and is projected to grow at a substantial CAGR during the forecast period. The growing adoption by commercial pig farms and better vaccine selection availability contribute to driving the segmental market growth. On the other hand, the government tender segment is a growing segment in the classical swine fever vaccines market. These tenders focus on procuring high-quality cell culture vaccines, like those developed by ICAR-IVRI.

Regional Segment Analysis of the Classical Swine Fever Vaccines Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

Asia Pacific is anticipated to hold the largest share of the classical swine fever vaccines market over the predicted timeframe.

Asia Pacific is anticipated to hold the largest share of about 70.0% in the classical swine fever vaccines market over the predicted timeframe. The market ecosystem in Asia Pacific is strong, driven by increased demand for classical swine fever vaccines due to large-scale pig farming and prevalence of disease outbreaks. China is leading the Asia Pacific classical swine fever vaccines market, due to increased market authorization for classical swine fever live vaccine developed by multinational companies and research institutes.

Europe is expected to grow at a rapid CAGR of approximately 9.1% in the classical swine fever vaccines market during the forecast period. The Europe region has a thriving market for classical swine fever vaccines due to increased risk of classical swine fever, along with an increased emphasis on the significance of EU rules for trade in pigs and their products. Germany is the leading country in the region’s market, owing to the robust disease prevention measures by farmers and the government for livestock assets and food security.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the classical swine fever vaccines market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Boehringer Ingelheim
• WINSUN Bio
• Merck Animal Health
• CAHIC
• SPAH
• Tecon Group
• Ringpu Biology
• Bioveta
• Institut Pasteur
• Komipharm
• Jinyu Bio-Technology
• Agrovet
• Qilu Animal Health
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

In November 2025, the agriculture ministry unveiled its plan to make Korea free of classic swine fever (CSF) and minimize outbreaks of other major viral diseases affecting pigs, such as porcine epidemic diarrhea (PED) and porcine reproductive and respiratory syndrome (PRRS), by 2030.  

In May 2024, the US Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) announced an investment of $22.2 million in disease prevention, preparedness, early detection and rapid response for threats to US livestock.

In March 2024, the Indian Institute of Technology-Guwahati transferred the technology to produce the country's first recombinant vaccine against classical swine fever to the biotech firm Bio-Med.

In May 2023, Q-Vant Biosciences announced positive results comparing Q-Vant's sustainable saponin-based adjuvant, Q-VET-S, to Croda’s Quil-A adjuvant. These results were obtained through a collaborative study with Kansas State University, utilizing their subunit classic swine fever vaccine.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Classical Swine Fever Vaccines Market based on the below-mentioned segments: 

Global Classical Swine Fever Vaccines Market, By Source

• Tissue Culture Origin
• Cell Line Origin

Global Classical Swine Fever Vaccines Market, By Application

• Government Tender
• Market Sales

Global Classical Swine Fever Vaccines Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa